https://www.selleckchem.com/pr....oducts/butyzamide.ht
89; 95% CI, 0.86-0.92), heart-rhythm monitoring (OR 0.92; 95% CI, 0.87-0.98), echocardiography (OR 0.92; 95% CI, 0.89-0.95), evaluation by a neurologist (OR 0.94; 95% CI, 0.91-0.97), and evaluation by a vascular neurologist (OR 0.94; 95% CI, 0.90-0.97), after adjustment for age, race, and comorbidities. These findings were unchanged in separate sensitivity analyses excluding patients who died during the index hospitalization or were discharged to hospice and excluding patients with atrial fibrillation diagnosed before their index str
Gefällt mir
Kommentar
Teilen
